Company
Patrys Ltd
ASX:PAB
Based in Melbourne, Australia, Patrys is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications.
68 stories · page 1 of 4
Patrys strengthens board with appointment of pharma executive as chairman
Dr Charmaine Gittleson’s expertise spans many aspects of the pharmaceutical industry, from drug development and clinical research to strategic planning and executive management.
Patrys' preclinical data demonstrates PAT-DX3 can cross blood-brain barrier 3-4 times more effectively than control
“These properties open up a range of applications for using deoxymabs to deliver small molecule therapeutics and gene editing technologies directed to various neurological targets and conditions," said CEO and MD Dr James Campbell.
Patrys hunts for new chair as company secretary takes on extra duties
The company has appointed Stefan Ross as a non-executive director and is also on the hunt for a new chair following John Read’s retirement.
Patrys readies PAT-DX1 for the clinic after passing specification tests
The company is putting in the groundwork ahead of a Phase 1 clinical trial, which is slated to kick off in the second half of next year.